Michael Gladstone is a principal and focuses on new platform company creation and operations. Michael was a member of the founding teams of several Atlas Venture-originated companies, including Padlock Therapeutics (acquired by BMS), Surface Oncology, and IFM Therapeutics. He serves as a board member of Obsidian Therapeutics and as a board observer for IFM Therapeutics, Kyn Therapeutics, Replimune, and AvroBio; he was previously a board observer for Delinia (acquired by Celgene). He has also been closely involved with Atlas’s immuno-oncology investments CoStim Pharmaceuticals (acquired by Novartis) and Unum Therapeutics.
Prior to joining Atlas in 2012, Michael was a senior associate consultant in the life sciences practice at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. Prior to that, Michael was a Massachusetts Life Sciences Center Fellow at Eutropics, a Dana Farber Cancer Institute spin out, where he helped develop BH3 domain focused therapeutics and companion diagnostics for multiple myeloma and other malignancies. Previously, Michael worked in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center where he led research on cellular HIV vaccines with Harvard Medical School Professor Norman Letvin. His research focused on elucidating the role of interleukin-21 in CD8+ T cell memory response to viral antigens.
Michael received an AB in biochemical sciences with highest honors from Harvard College, where he graduated magna cum laude and was awarded the Harvard College Scholarship. While at Harvard, he received a Herchel Smith Undergraduate Fellowship, among other grants, for his undergraduate immunology research. Michael is on the Corporate Advisory Committee for National Tay-Sachs and Allied Diseases, a national organization focused on funding research, promoting awareness, and supporting families affected by Tay-Sachs and related genetic diseases.